Story perspectives

New Treatment Boosts Glioblastoma Survival by 70%!

6/10/2025

26 2

Summary

Story summary

A groundbreaking study from USC shows that pairing Tumor Treating Fields (TTFields) with immunotherapy and chemotherapy boosts glioblastoma survival rates by an astonishing 70%. Patients with inoperable tumors are living 13 months longer than anticipated. This innovative treatment disrupts tumor growth and strengthens immune responses, igniting hope for those battling this fierce brain cancer. A Phase 3 trial is set to confirm these promising results.

1 of 1

Story summary

A groundbreaking study from USC shows that pairing Tumor Treating Fields (TTFields) with immunotherapy and chemotherapy boosts glioblastoma survival rates by an astonishing 70%. Patients with inoperable tumors are living 13 months longer than anticipated. This innovative treatment disrupts tumor growth and strengthens immune responses, igniting hope for those battling this fierce brain cancer. A Phase 3 trial is set to confirm these promising results.